North America Biomarkers Market

The report "North America Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)—Forecast to 2030" is projected to grow from USD 42.25 billion by 2030 and to reach USD 25.13 billion in 2025, at a Compound Annual Growth Rate (CAGR) of 11.0% during the forecast period.

Browse 708 market data Tables and 56 Figures spread through 506 Pages and in-depth TOC on "North America Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)—Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/north-america-biomarkers-market-74094793.html

The North America biomarkers market is growing, driven by several key factors, including the adoption of precision medicine and companion diagnostics, and advances in healthcare infrastructure and R&D investment.

The safety biomarkers segment accounted for the largest share by type segment in the North America biomarkers market in 2024.

The North America biomarkers market is segmented into safety, efficacy, and validation biomarkers. Efficacy biomarkers are further categorized into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. The safety biomarkers segment accounted for the largest share of the biomarkers market in 2024. This is due to the adoption of safety biomarkers in drug development, advances in techniques and tools for toxicity testing, and early detection of potential adverse reactions. Regulatory bodies are demanding the use of safety biomarkers in candidate drugs to evaluate safety standards before progressing to other stages of clinical testing. In addition, drug manufacturers are investing in safety biomarker strategies to lower the risk of late-stage failures and enhance decision-making in earlier stages, including preclinical trials.  

In 2024, the NGS segment is expected to be the fastest-growing in the North America biomarkers market, by application.

The North America biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. NGS technology is estimated to register the highest CAGR during the forecast period of 2025-2030. Next-generation sequencing (NGS) refers to a group of high-throughput DNA and RNA sequencing technologies that can read millions of fragments in parallel, enabling rapid, large-scale genomic analysis. These platforms underpin many biomarker applications, including whole-genome and exome sequencing, targeted gene panels, RNA-seq, and single-cell sequencing, which support the discovery and validation of complex genomic, transcriptomic, and epigenetic biomarkers in oncology and other disease areas.

The US accounted for the largest regional share in the North America biomarkers market in 2024.

The North America biomarkers market is divided primarily between the US and Canada, with the US accounting for the largest share of regional revenues. The country’s dominance reflects its dense concentration of biopharma headquarters, academic medical centers, and specialized reference laboratories, along with strong FDA oversight and rapid adoption of advanced diagnostic platforms and companion tests. Large oncology and immunology pipelines, robust NIH and cancer-focused funding, and an active clinical-trials ecosystem further cement the US as the primary engine of biomarker demand within North America.

Key players in the pharmaceutical filtration market include Abbott (US), Thermo Fisher Scientific Inc (US), Revvity (US), Laboratory Corporation Of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc (US), Agilent Technologies, Inc (US), Quanterix (US).

Don’t miss out on business opportunities in North America Biomarkers Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/